The IC50 values were inversely proportional to TF-mRNA levels, achieving 1000 to >5000 fold target selective cytotoxicity in high-TF TNBC and PaC tumor cells (Figure 7D, Supplementary Figure 4B, 4D) thus validating the potential utility of SC1-ADCs in TF-targeted treatment. The gene discussed is TF; the disease is neoplasm.